AKR.L Share Price (AKR)

As nobody has made a comment regarding the delisting shortly. I have sold most of my shares in this company now ( last week ) , i did make some money in the past with this share but when they moved to the Nasdaq i think they pushed there luck too far and they slowly robbed us of our shares . You would have thought they would have just moved our shares to the US market but by not doing that they gain £ 10 million. clever. The only good point is we have been told properly by our brokers and not under the table job like Flybe RIP OFF. But they need 75 % t do that so what happens then if not passed. Any thoughts.

Just about says it all. Proposal to de-list announced on 19th December, and not a single posting here! What a pile of excrement this has turned out to be.

https://www.investegate.co.uk/akers-biosciences--akr-/rns/further-re--strategic-update/201811191400037967H/

For every 8 it is now just one so it is actually down. ( 16.25p @ 130 )

The board of directors at Akers Biosciences Inc. said Wednesday the South Jersey medical-device company has "initiated a process to evaluate strategic alternatives to maximize shareholder value."

Based in Thorofare, Gloucester County, Akers develops and markets rapid screening and testing products for use in health care.

The board said the evaluations process will consider a range of potential strategic alternatives "including, but not limited to, business combinations." Akers said company representatives do not plan to disclose or comment on developments regarding the strategic review process until it is complete, or further disclosure is deemed appropriate.

“The board of directors and management of the company believes that now is the right time to review strategic alternatives to assess how best to maximize value for our shareholders," said Howard R. Yeaton, CEO of Akers. "During this process, the team will remain focused on advancing our current business operations and serving our customers.”

Yeaton was named CEO at Akers in October, the same month the company settled a lawsuit in part by agreeing to discontinue marketing efforts for its BreathScan OxiChek product or any product that detects oxidative stress in exhaled human breath.

The company said last month it will focus on its Particle Immuno-Filtration Assay (PIFA) technology platform that features a patented immunoassay method for rapidly and accurately detecting targeted antigens or antibodies. The technology platform is used in Akers PIFA Heparin/PF4 and PIFA Pluss/PF4 rapid assays that test for an allergic reaction to the blood-thinning medicine Heparin. These products, the company said, account for the “significant majority” of its revenues.

Akers also said Wednesday that the company to meet Nasdaq's minimum listing requirement of a minimum $1 per share stock price for companies listed on the exchange will implement a one-for-eight reverse stock split on Nov. 8.

TRENDING
BANKING & FINANCIAL SERVICES
Citizens Financial to acquire wealth management firm
As part of its continuing focus on expanding its fee product offerings, Citizens Financial Group has agreed to acquire a Westchester County, New York wealth management firm.
CAREER & WORKPLACE
Philadelphia Business Journal's Power 100, Part 5

COMING EVENT
Banking on Change: Greater Philadelphia’s Shifting Financial Landscape
Nov. 13

Its common stock will continue to trade on the Nasdaq Capital Market under the stock ticker "AKER."